For example, the overexpression of EZH2 is common within non-small-cell lung carcinoma (NSCLC) [13,14], colorectal cancer (CRC) associated with claudin-23 (CLDN23) and Runt-related transcription factor 3 (RUNX3) [15,16], aggressive forms of breast cancer [17,18,19,20], Ras signaling-based pancreatic cancer [21,22], and hormone-refractory prostate cancer [23,24]. This evidence concerns the gene CLDN23 and breast cancer.